Aims to provide cell therapy R&D with standardized MSC products, optimized culture media, and cryopreservation solutions.

CellProthera will tech transfer to CELLforCURE by SEQENS this year, with plans to produce clinical batches starting in 2026.

The previously announced ASTM D4169-22 and ISTA Package Distribution Testing Service expansions are now fully operational.

Shift Bioscience (Shift), a biotech company using an AI-powered virtual cell to fight age-driven diseases, appointed Lord ...

Zealand Pharma A/S, a biotechnology company, has appointed Steven Johnson as Chief Development Officer.

GC Biopharma has partnered with Körber to implement a large-scale Manufacturing Execution System (MES) project across ...

This designation highlights the potential of Cellino’s automated technology for scaling up high-quality iPSCs to industrialize next-generation regenerative therapies. Autologous ...

The U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Novavax Inc.’s Nuvaxovid.

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a ...

BioMarin has entered into a definitive agreement to acquire Inozyme Pharma Inc. for a total consideration of approximately ...

Lars Fruergaard Jørgensen will step down from his role as CEO of Novo Nordisk. In the meantime, a search for Jørgensen’s ...

The new board will work with Abzena's scientific and commercial leadership to provide strategic guidance and insights.